Ficlatuzumab is under clinical development by AVEO Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Ficlatuzumab’s likelihood of approval (LoA) and phase transition for Recurrent Head And Neck Cancer Squamous Cell Carcinoma took place on 23 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Ficlatuzumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Ficlatuzumab (AV-299, SCH 900105) is under development for the treatment of advanced or recurrent/metastatic head and neck squamous cell carcinoma, nasopharyngeal cancer, metastatic pancreatic ductal adenocarcinoma and metastatic adenocarcinoma of the pancreas. It is a functional anti-hepatocyte growth factor (HGF) monoclonal antibody. It is administered intravenously through infusion. Through the use of human response platform, the HGF/c-Met pathway identified as a significant driver of tumor growth.
It was also under development for the treatment of non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, undifferentiated carcinoma, or poorly differentiated carcinoma of the oral cavity, oropharynx, larynx, or hypopharynx, relapsed or refractory acute myeloid leukemia, advanced metastatic colorectal, head and neck squamous cell carcinoma, breast, gastric/esophageal cancer with liver metastases and advanced solid tumors such as non-small cell lung cancer.
AVEO Pharmaceuticals overview
AVEO Pharmaceuticals (Aveo), is a biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of various types of cancers. Its flagship product tivozanib is approved as a first-line treatment for adult patients with renal cell carcinoma and marketed under the brand name Fotivda in European Union, Iceland and Norway. The company’s clinical product includes Ficlatuzumab, a hepatocyte growth factor inhibitory antibody, and AV-203, an anti-ErbB3 monoclonal antibody. It also has pre-clinical products in the pipeline. The company develops products through strategic partnerships with other pharmaceutical companies. Aveo is headquartered in Boston, Massachusetts, the US.
Quick View Ficlatuzumab LOA Data
|Highest Development Stage|